AVROBIO is one of a handful of gene therapy companies with pipelines that include Pompe disease. Today they’ve announced a halt to their programs. AVROBIO also recently announced a sale of their Cystinosis gene therapy program. Their current programs in Gaucher and MPS were more advanced than their Pompe program. As they restructure with an emphasis on shareholder value, we hope that they can find a way to achieve that goal as well as their core goal, “… to enable individuals with genetic disease to live longer — free from disease progression, free from painful and debilitating symptoms and free from the burden of chronic treatment regimens.”

Source: investors.avrobio.com/news-releases/news-release-details/avrobio-explore-strategic-alternatives

Tagged: gene therapy